Your browser doesn't support javascript.
Specific Susceptibility to COVID-19 in Adults with Down Syndrome.
Illouz, Tomer; Biragyn, Arya; Frenkel-Morgenstern, Milana; Weissberg, Orly; Gorohovski, Alessandro; Merzon, Eugene; Green, Ilan; Iulita, Florencia; Flores-Aguilar, Lisi; Dierssen, Mara; De Toma, Ilario; Lifshitz, Hefziba; Antonarakis, Stylianos E; Yu, Eugene; Herault, Yann; Potier, Marie-Claude; Botté, Alexandra; Roper, Randall; Sredni, Benjamin; Sarid, Ronit; London, Jacqueline; Mobley, William; Strydom, Andre; Okun, Eitan.
  • Illouz T; The Leslie and Susan Gonda Multidisciplinary Brain Research Center, Bar-Ilan University, 5290002, Ramat-Gan, Israel.
  • Biragyn A; The Paul Feder Laboratory On Alzheimer's Disease Research, Bar-Ilan University, 5290002, Ramat-Gan, Israel.
  • Frenkel-Morgenstern M; Laboratory of Molecular Biology and Immunology, NIA, Baltimore, MD, 21224, USA.
  • Weissberg O; Cancer Genomics and BioComputing of Complex Diseases Lab, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
  • Gorohovski A; Cancer Genomics and BioComputing of Complex Diseases Lab, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
  • Merzon E; Cancer Genomics and BioComputing of Complex Diseases Lab, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
  • Green I; Leumit Health Services, Department of Family Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.
  • Iulita F; Leumit Health Services, Department of Family Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.
  • Flores-Aguilar L; Sant Pau Memory Unit, Department of Neurology, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
  • Dierssen M; Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • De Toma I; Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
  • Lifshitz H; Alzheimer-Down Unit, Fundación Catalana Síndrome de Down, Barcelona, Spain.
  • Antonarakis SE; Department of Anatomy and Cell Biology, McGill University, Montreal, Canada.
  • Yu E; Center for Genomic Regulation, The Barcelona Institute for Science and Technology, Barcelona, Spain.
  • Herault Y; University Pompeu Fabra, Barcelona, Spain.
  • Potier MC; Biomedical Research Networking Center for Rare Diseases (CIBERER), Barcelona, Spain.
  • Botté A; Cellular & Systems Neurobiology, Systems Biology Program, The Barcelona Institute of Science and Technology, Centre for Genomic Regulation (CRG), Dr. Aiguader 88, 08003, Barcelona, Spain.
  • Roper R; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Sredni B; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
  • Sarid R; School of Education, Bar-Ilan University, 5290002, Ramat-Gan, Israel.
  • London J; Department of Genetic Medicine and Development, University of Geneva, 1211, Geneva, Switzerland.
  • Mobley W; Medigenome, Swiss Institute of Genomic Medicine, 1207, Geneva, Switzerland.
  • Strydom A; iGE3 Institute of Genetics and Genomics of Geneva, 1211, Geneva, Switzerland.
  • Okun E; The Children's Guild Foundation Down Syndrome Research Program, Genetics and Genomics Program and Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Neuromolecular Med ; 23(4): 561-571, 2021 12.
Article in English | MEDLINE | ID: covidwho-1525619
ABSTRACT
The current SARS-CoV-2 outbreak, which causes COVID-19, is particularly devastating for individuals with chronic medical conditions, in particular those with Down Syndrome (DS) who often exhibit a higher prevalence of respiratory tract infections, immune dysregulation and potential complications. The incidence of Alzheimer's disease (AD) is much higher in DS than in the general population, possibly increasing further the risk of COVID-19 infection and its complications. Here we provide a biological overview with regard to specific susceptibility of individuals with DS to SARS-CoV-2 infection as well as data from a recent survey on the prevalence of COVID-19 among them. We see an urgent need to protect people with DS, especially those with AD, from COVID-19 and future pandemics and focus on developing protective measures, which also include interventions by health systems worldwide for reducing the negative social effects of long-term isolation and increased periods of hospitalization.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Down Syndrome / Disease Susceptibility / COVID-19 Type of study: Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Adolescent / Adult / Female / Humans / Male Language: English Journal: Neuromolecular Med Journal subject: Molecular Biology / Neurology Year: 2021 Document Type: Article Affiliation country: S12017-021-08651-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Down Syndrome / Disease Susceptibility / COVID-19 Type of study: Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Adolescent / Adult / Female / Humans / Male Language: English Journal: Neuromolecular Med Journal subject: Molecular Biology / Neurology Year: 2021 Document Type: Article Affiliation country: S12017-021-08651-5